With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
gwyneth@intlabmate.com The latest business developments from across Europe & Middle East
by Gwyneth Astles
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Strategic partnership to accelerate drug discovery with X-ray crystallography
The partnership combines Concept’s integrated drug discovery process with Accelero’s crystallography- based fragment screening for hit generation and iterative crystallography-driven inhibitor optimisation. Together, they will provide clients with effi cient hit-to- lead development, improving key factors such as target affi nity, selectivity, and ADME properties. This is expected to signifi cantly reduce development timelines and deliver faster transitions from discovery to clinical stages, which in many cases could be faster by ten times.
Ben Cliff, CEO of Concept Life Sciences.
Debanu Das, Co-Founder and CEO of Accelero Biostructures.
Concept Life Sciences, a UK-based drug discovery specialist, has joined forces with Accelero Biostructures, a US-based leader in X-ray crystallography, to accelerate early drug discovery. This partnership integrates cutting- edge structural biology with comprehensive drug development expertise, aiming to reduce drug discovery timelines by up to tenfold.
By combining Concept’s broad capabilities - including biophysics, medicinal chemistry, and pharmacology - with Accelero’s proprietary X-ray crystallography platforms, the collaboration provides pharma companies with an advanced, structure-based approach to hit identifi cation and lead optimisation.
Accelero’s high-throughput ABS-ServicesSM and ABS- OneStepSM platforms deliver rapid and precise protein- ligand interaction data, enabling informed drug design, even for challenging targets. These insights, paired with Concept’s iterative optimisation strategies, streamline the progression from hit discovery to clinical candidate selection.
“This collaboration unites two complementary teams with a shared vision to push the boundaries of drug discovery,” said Debanu Das, Co-Founder and CEO of Accelero Biostructures. “Together, we can enhance the quality and speed of early-stage development, helping our clients bring novel therapies to patients faster.”
Ben Cliff, CEO of Concept Life Sciences, added: “By partnering with Accelero, we strengthen our ability to support biopharma innovators with cutting-edge structural biology and integrated discovery expertise. This alliance reinforces our commitment to scientifi c rigor and effi ciency, accelerating the journey from discovery to clinical development.”
The partnership is already driving progress, with multiple collaborative projects underway. By utilising their combined strengths, Concept and Accelero are positioned to deliver transformative impact in the global drug discovery landscape.
More information online:
ilmt.co/PL/BNx1 63806pr@reply-direct.com
Collaboration expands genomic testing in clinical trials
Biofi delity, a leader in innovative genomic solutions, has entered into a strategic partnership with CellCarta, a global contract research organisation (CRO) specialising in precision medicine solutions. This collaboration will integrate Biofi delity’s Aspyre® Lung assay into CellCarta’s clinical trial services, expanding access to advanced genomic testing worldwide.
Aspyre Lung streamlines the detection of key non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood samples. Utilising a simple four-step workfl ow, it operates on existing qPCR platforms, making it a seamless addition to clinical laboratories. By incorporating this technology, CellCarta aims to enhance its biomarker testing capabilities, supporting effi cient and reliable patient enrollment in clinical trials.
Under the agreement, CellCarta will fi rst establish and validate Aspyre Lung in its European laboratories before expanding to its US-based facilities. The partnership grants CellCarta non-exclusive rights to utilise Aspyre Lung for clinical trials globally, offering pharmaceutical and biotech companies access to cutting-edge genomic profi ling for both liquid and tissue biopsy samples.
Partnership to strengthen Saudi biopharmaceutical manufacturing
Batavia Biosciences, a leading contract development and manufacturing organisation, is expanding its partnership with PrexPharma, an emerging player in the Saudi Arabian biopharmaceutical sector. This collaboration marks a pivotal step in driving the growth of biopharmaceutical products, including biosimilars and recombinant proteins, within the Saudi market.
PrexPharma, the fi rst commercial parental biomanufacturing facility in the MENA region, is aligned with Saudi Arabia’s Vision 2030. The company’s mission to advance local R&D, create job opportunities, and improve patient access to essential medicines is integral to the nation’s shift toward a non-oil-based economy.
As part of this expanded partnership, Batavia Biosciences will provide support in product registration and local manufacturing for several biopharmaceutical products. Batavia will conduct in-depth reviews of product dossiers to ensure compliance with Saudi Food and Drug Authority (SFDA) regulations and evaluate the manufacturability of these products at PrexPharma’s facilities.
A dedicated team within Batavia, led by an experienced senior expert, will oversee the project, bringing extensive expertise in R&D, technology transfer, and regulatory compliance. This team will thoroughly review critical
documentation, such as product dossiers, quality assurance records, and GMP compliance documents, ensuring an effi cient and comprehensive evaluation process.
“PrexPharma selected Batavia Biosciences for our proven expertise in developing a wide range of biological products, our experience in technology transfer, and our success in meeting regulatory standards across the EMA and FDA. Our ability to assess manufacturability, including cost of goods (COGs) and scalability, positions us as a key partner for PrexPharma’s biopharmaceutical growth,” said Ahd Hamidi, Strategic Partnership Director at Batavia Biosciences.
“This partnership goes beyond fulfi lling immediate regulatory requirements; it is a long-term collaboration aimed at supporting Saudi Arabia’s local biomanufacturing industry. By combining our expertise, we are committed to accelerating PrexPharma’s expansion within the MENA region and internationally.”
More information online:
ilmt.co/PL/n3o0 63808pr@reply-direct.com
“We are thrilled to collaborate with CellCarta to bring Aspyre Lung to global clinical trials,” said Barnaby Balmforth, PhD, Co-Founder and CEO of Biofi delity. “By simplifying genomic profi ling, we are making precision medicine more accessible, and this partnership marks a signifi cant step in accelerating trial enrollment and improving patient outcomes.”
Dusty Tenney, CEO of CellCarta, echoed the enthusiasm: “CellCarta is dedicated to advancing precision medicine through specialised laboratory services. Integrating Aspyre Lung into our biomarker testing portfolio strengthens our ability to deliver high-quality, effi cient solutions to pharmaceutical and biotech partners.”
This partnership reinforces both companies’ commitment to driving innovation in clinical genomics, ensuring that novel therapies reach patients faster.
More information online:
ilmt.co/PL/KmJj 63807pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the Europe and Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
